SCHEMBL2084689

SCHEMBL2084689

Cc1cccnc1CNCc1ncccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 10/20 0.44
ADORA1 P30542 8/20 0.44
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
HTT P42858 1/20 0.36
SLC40A1 Q9NP59 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
IGF1R P08069 1/20 0.35
FGFR1 P11362 1/20 0.35
KDR P35968 1/20 0.35
RAB9A P51151 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
MAPK1 P28482 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082460 0.89 NOS3 (0.45) ADORA2AADORA1MAOAMAOBNOS3
SCHEMBL2261106 0.80 NOS3 (0.41) ADORA2AADORA1MAOAMAOBNOS3
SCHEMBL25378467 0.79 HTT (0.50) ADORA2AADORA1NOS2HTTL3MBTL1
SCHEMBL25377053 0.79 KDM4A (0.46) MAOAKDM4EMAPK1MEN1KMT2A
SCHEMBL16268719 0.79 CD274 (0.46) ADORA2AADORA1HTTSLC40A1L3MBTL1
SCHEMBL11710579 0.78 NPC1 (0.50) ADORA2AADORA1L3MBTL1RAB9ANPC1
SCHEMBL30481998 0.78 SCN8A (0.55) MAOAMAOBL3MBTL1RAB9AKDM4E
SCHEMBL2085284 0.77 MAOA (0.40) ADORA2AADORA1MAOAMAOBNOS3
SCHEMBL7995737 0.76 SLC40A1 (0.38) SLC40A1RAB9ANPC1MAPK1MEN1
SCHEMBL4620705 0.76 SCN8A (0.42) ADORA2AADORA1NOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613613-B1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2021-06-02 EP disclosed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
EP-1613613-A4 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2009-03-25 EP disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed
EP-1613613-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-01-11 EP disclosed
WO-2004091518-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2004-10-28 WO disclosed
US-20040209921-A1 CXCR4 chemokine receptor binding comounds ANORMED CORPORATION (CA) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209921-A1 CXCR4 chemokine receptor binding comounds CXCR4, CXCR1, CXCR3 ADORA2A 66/4885ADORA1 70/4885MAOA 4294/4885
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 ADORA2A 58/4885ADORA1 53/4885MAOA 4367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.